Kyverna Therapeutics, Inc. 8-K

What Happened

• Kyverna Therapeutics, Inc. announced an amendment (effective June 30, 2026; entered July 8, 2026) to its Loan and Security Agreement with Oxford Finance LLC and participating lenders. The original loan facility provides up to $150.0 million in multiple tranches (Term A, Term B and Term C). Kyverna previously drew $25.0 million of Term A on November 3, 2025.
• Under the Amendment, the Company extended the availability of the remaining $15.0 million of Term A loans through December 31, 2026 in exchange for a $187,500 upfront cash fee. If Kyverna does not draw the full $15.0 million by that date, it will owe a non‑utilization fee equal to 1.0% of the undrawn amount.

Key Details

• Original facility: up to $150.0 million across Term A (up to $40.0M), Term B ($5.0M–$20.0M), and Term C (up to $40.0M).
• Draws to date: $25.0 million drawn from Term A on November 3, 2025; $15.0 million remaining under Term A.
• Amendment fees: $187,500 upfront fee; 1.0% non‑utilization fee on any undrawn portion of the remaining Term A if not borrowed by December 31, 2026.
• Contingent changes if Kyverna draws the full $15.0M: extended Term B draw window (through earlier of Sept 30, 2027 or 90 days after a clinical milestone), 1.0% non‑utilization fee for Term B if unused, Term C split into two $20.0M tranches with milestone timing through Mar 31, 2028, and minimum revenue covenants to begin in mid-to-late 2027 depending on other capital raised. If the $15.0M is not fully drawn, these contingent modifications do not take effect.

Why It Matters

• Liquidity and flexibility: The amendment gives Kyverna more time (to Dec 31, 2026) to access the remaining $15.0M of Term A debt, helping near-term funding options without issuing equity. However, the Company pays an upfront fee and faces a penalty if it does not use the full amount.
• Future obligations: If Kyverna draws the full remaining Term A amount, the loan facility could impose revenue-based covenants and additional non‑utilization fees tied to future tranches, which may affect financial flexibility beginning in 2027 depending on the Company’s cash raises and milestone progress.
• Investor takeaway: Watch whether Kyverna draws the remaining $15.0M and whether it meets the clinical/revenue milestones that would trigger additional tranches and covenants—those outcomes affect dilution (non‑dilutive debt vs. equity), leverage, and operational constraints.